ECONOMIC IMPACT OF A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION PROGRAMME IN A MEXICAN CORPORATE SETTING

被引：1
|
作者：
Huicochea-Bartelt, J. L. [1 ]
Mucino-Ortega, E. [1 ]
Vargas-Valencia, J. J. [2 ]
机构：
[1] Pfizer SA CV, Ciudad De Mexico, Mexico
[2] Econopharma Consulting SA CV, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1612
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN69
引用
收藏
页码：A277 / A277
页数：1
相关论文
共 50 条
  • [41] Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
    Rodrigo, Chamira
    Bewick, Thomas
    Sheppard, Carmen
    Greenwood, Sonia
    Mckeever, Tricia M.
    Trotter, Caroline L.
    Slack, Mary
    George, Robert
    Lim, Wei Shen
    EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (06) : 1632 - 1641
  • [42] Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
    Bruce, Michael G.
    Singleton, Rosalyn
    Bulkow, Lisa
    Rudolph, Karen
    Zulz, Tammy
    Gounder, Prabhu
    Hurlburt, Debby
    Bruden, Dana
    Hennessy, Thomas
    VACCINE, 2015, 33 (38) : 4813 - 4819
  • [43] Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
    Ghia, Canna J.
    Horn, Emily K.
    Rambhad, Gautam
    Perdrizet, Johnna
    Chitale, Ramaa
    Wasserman, Matt D.
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2271 - 2288
  • [44] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
    Bhorat, As'ad E.
    Madhi, Shabir A.
    Laudat, France
    Sundaraiyer, Vani
    Gurtman, Alejandra
    Jansen, Kathrin U.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    AIDS, 2015, 29 (11) : 1345 - 1354
  • [45] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
    Duggan, Sean T.
    DRUGS, 2010, 70 (15) : 1973 - 1986
  • [46] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
    Sean T. Duggan
    Drugs, 2010, 70 : 1973 - 1986
  • [47] Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination
    Heinsbroek, Ellen
    Tafatatha, Terence
    Phiri, Amos
    Swarthout, Todd D.
    Alaerts, Maaike
    Crampin, Amelia C.
    Chisambo, Christina
    Mwiba, Oddie
    Read, Jonathan M.
    French, Neil
    VACCINE, 2018, 36 (48) : 7369 - 7376
  • [48] The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease
    Principi, Nicola
    Esposito, Susanna
    EXPERT REVIEW OF VACCINES, 2015, 14 (10) : 1359 - 1366
  • [49] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to pneumococcal vaccination
    Wysocki, Jacek
    Brzostek, Jerzy
    Szymanski, Henryk
    Tetiurka, Boguslaw
    Toporowska-Kowalska, Ewa
    Wasowska-Krolikowska, Krystyna
    Sarkozy, Denise A.
    Giardina, Peter C.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    VACCINE, 2015, 33 (14) : 1719 - 1725
  • [50] Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years
    Weycker, Derek
    Sato, Reiko
    Strutton, David
    Edelsberg, John
    Atwood, Mark
    Jackson, Lisa A.
    VACCINE, 2012, 30 (36) : 5437 - 5444
12345